Nasdaq · CIK 0001178670 · PHARMACEUTICAL PREPARATIONS
ALNYLAM PHARMACEUTICALS, INC.
ALNY chart by TradingView
PRICE HISTORY
LIVE · NASDAQALNY chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $3.7B
- EBITDA
- $0.6B
- FREE CASH FLOW
- $0.5B
- EPS
- $2.33
- GROSS MARGIN
- 81.77%
- ROIC
- —
Q1 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
83.8x
-90%83.8x815.1x
⤢
P / SALES (TTM)
9.4x
-84%9.4x57.3x
⤢
P / BOOK
30.7x
+251%8.7x1093.1x
⤢
EV / EBITDA (TTM)
—
⤢
EV / REVENUE (TTM)
—
-33%20.1x30.0x
⤢
FCF YIELD (TTM)
—
+4.2pp-5.12%1.04%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$1.3B
+14723%⤢
EBITDA (DERIVED)
—
+$0.2B⤢
NET INCOME
$0.2B
+$0.3B⤢
EPS (DILUTED)
$1.19
+$3.72⤢
REVENUE GROWTH YOY
117.26%
+117.0pp-87.90%3286.23%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
—
+1067.2pp-9628.66%598.14%
⤢
RETURN ON CAPITAL
—
-231.8pp-875.54%-118.71%
⤢
RETURN ON EQUITY (TTM)
36.67%
+69.5pp-1026.96%39.76%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN76.90%
OPERATING MARGIN17.93%
NET MARGIN12.74%
FCF MARGIN—
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
—
+$0.2B⤢
STOCK-BASED COMP
$0.1B
+448%⤢
CAPITAL EXPENDITURE
—
+8%⤢
SHARES OUTSTANDING
0.14B
+27%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$1.7B
+530%⤢
TOTAL DEBT
—
+254%⤢
DEBT / EBITDA (TTM)
—
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 102.17%INSIDERS 0.18%OTHER / RETAIL 0.00%1,174 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| FMR, LLC | 10.90% | 14.6M | $3.20B | -8.3% |
| Capital World Investors | 8.07% | 10.8M | $2.37B | -33.7% |
| Blackrock Inc. | 7.81% | 10.4M | $2.29B | +0.4% |
| Capital Research Global Investors | 7.08% | 9.5M | $2.08B | +39.7% |
| Vanguard Portfolio Management LLC | 4.85% | 6.5M | $1.42B | NEW |
| JPMORGAN CHASE & CO | 4.73% | 6.3M | $1.39B | +34.0% |
| Vanguard Capital Management LLC | 4.44% | 5.9M | $1.30B | NEW |
| T. Rowe Price Investment Management, Inc. | 3.88% | 5.2M | $1.14B | +196.1% |
| Invesco Ltd. | 3.05% | 4.1M | $893.3M | -20.6% |
| State Street Corporation | 2.48% | 3.3M | $728.3M | +2.9% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.